BioPharmSignal logoBioPharmSignal

Biotech News

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Pulmonx (LUNG)Pulmonx2026-06-25 13:46 ESTEarnings

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Open original release

Related news

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx to Participate in September Investor Conferences

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx Reports Third Quarter 2025 Financial Results

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx Announces Closing of up to $60 Million Credit Facility

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx Reports First Quarter 2026 Financial Results

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

View all latest news

Pulmonx

Pulmonx is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

LUNGPulmonx2026-06-26 08:21 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-06-26 08:21 EST

Pulmonx to Participate in September Investor Conferences

LUNGPulmonx2026-06-26 08:21 EST

Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

LUNGPulmonx2026-06-26 08:21 EST

Pulmonx Reports Third Quarter 2025 Financial Results

LUNGPulmonx2026-06-26 08:21 EST

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States